Jafron Biomedical Co (SZSE:300529) Accounts Payable & Accrued Expense : ¥565 Mil (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Jafron Biomedical Co Accounts Payable & Accrued Expense?

Jafron Biomedical Co's quarterly accounts payable & accrued expense increased from Sep. 2023 (¥468 Mil) to Dec. 2023 (¥505 Mil) and increased from Dec. 2023 (¥505 Mil) to Mar. 2024 (¥565 Mil).

Jafron Biomedical Co's annual accounts payable & accrued expense declined from Dec. 2021 (¥360 Mil) to Dec. 2022 (¥348 Mil) but then increased from Dec. 2022 (¥348 Mil) to Dec. 2023 (¥505 Mil).

Jafron Biomedical Co Accounts Payable & Accrued Expense Historical Data

The historical data trend for Jafron Biomedical Co's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jafron Biomedical Co Accounts Payable & Accrued Expense Chart

Jafron Biomedical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

254.66

300.08

360.06

347.59

504.52

Jafron Biomedical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															409.34	472.13	467.88	504.52	565.13

Jafron Biomedical Co Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Jafron Biomedical Co (SZSE:300529) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Jafron Biomedical Co Ltd (SZSE:300529) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 98, Science and Technology 6th Road, High-tech Zone, Guangdong Province, Zhuhai, CHN, 519085

Website

http://www.jafron.com

Jafron Biomedical Co Ltd is a China-based company engaged in the research, development, production, and sales of biomaterials and medical devices. It offers solutions for kidney disease, poisoning, rheumatic immune solution, critical illness and liver disease. The company's products include JFYC-100 pre-punching machine, DX-10 blood purifier, and HA resin hemoperfusion.

Executives

Li Feng	Director
He Xiao Lian	Executives
Dong Fan	Directors, Directors, and Executives
Ceng Kai	Directors, executives
Tang Xian Min	Directors, executives
Zhang Ming Yuan	Secretary Dong
Fang Li Hua	Supervisors
Zhang Guang Hai	Directors, executives
Li De Zhi	Executives
Lu Shao Zhang	Executives

Jafron Biomedical Co (SZSE:300529) Headlines

No Headlines